Page last updated: 2024-09-03

peroxynitrous acid and bay 58-2667

peroxynitrous acid has been researched along with bay 58-2667 in 2 studies

Compound Research Comparison

Studies (peroxynitrous acid)	Trials (peroxynitrous acid)	Recent Studies (post-2010) (peroxynitrous acid)	Studies (bay 58-2667)	Trials (bay 58-2667)	Recent Studies (post-2010) (bay 58-2667)
3,303	21	1,230	104	6	69

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barnucz, E; Hirschberg, K; Karck, M; Korkmaz, S; Loganathan, S; Neugebauer, P; Páli, S; Radovits, T; Seidel, B; Szabó, G; Veres, G; Zöllner, S	1
Barnucz, E; Hegedüs, P; Hirschberg, K; Karck, M; Korkmaz, S; Li, S; Loganathan, S; Mikles, B; Páli, S; Radovits, T; Szabó, G; Weymann, A	1

Other Studies

2 other study(ies) available for peroxynitrous acid and bay 58-2667

Article	Year
Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury. Circulation, 2009, Aug-25, Volume: 120, Issue:8 Topics: Adrenergic beta-Agonists; Animals; Benzoates; Cardiotonic Agents; Cyclic AMP; Cyclic GMP; Cyclooxygenase 2; Dogs; Female; Gene Expression; Guanylate Cyclase; Heart Function Tests; Isoproterenol; L-Lactate Dehydrogenase; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide; Peroxynitrous Acid; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Survival Rate; Thiobarbituric Acid Reactive Substances; Transforming Growth Factor beta1	2009
Nitric oxide- and heme-independent activation of soluble guanylate cyclase attenuates peroxynitrite-induced endothelial dysfunction in rat aorta. Journal of cardiovascular pharmacology and therapeutics, 2013, Volume: 18, Issue:1 Topics: Animals; Aorta, Thoracic; Benzoates; Cyclic GMP; DNA Breaks; Endothelium, Vascular; Guanylate Cyclase; Heme; In Vitro Techniques; Male; Nitric Oxide; Oxidative Stress; Peroxynitrous Acid; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Vasodilation	2013

Article

Year

Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury.

Circulation, 2009, Aug-25, Volume: 120, Issue:8

Topics: Adrenergic beta-Agonists; Animals; Benzoates; Cardiotonic Agents; Cyclic AMP; Cyclic GMP; Cyclooxygenase 2; Dogs; Female; Gene Expression; Guanylate Cyclase; Heart Function Tests; Isoproterenol; L-Lactate Dehydrogenase; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide; Peroxynitrous Acid; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Survival Rate; Thiobarbituric Acid Reactive Substances; Transforming Growth Factor beta1

2009

Nitric oxide- and heme-independent activation of soluble guanylate cyclase attenuates peroxynitrite-induced endothelial dysfunction in rat aorta.

Journal of cardiovascular pharmacology and therapeutics, 2013, Volume: 18, Issue:1

Topics: Animals; Aorta, Thoracic; Benzoates; Cyclic GMP; DNA Breaks; Endothelium, Vascular; Guanylate Cyclase; Heme; In Vitro Techniques; Male; Nitric Oxide; Oxidative Stress; Peroxynitrous Acid; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Vasodilation

2013